BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 17549340)

  • 1. Detection of activated K-ras in non-small cell lung cancer by membrane array: a comparison with direct sequencing.
    Chong IW; Chang MY; Sheu CC; Wang CY; Hwang JJ; Huang MS; Lin SR
    Oncol Rep; 2007 Jul; 18(1):17-24. PubMed ID: 17549340
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detection of K-ras and p53 mutations in bronchoscopically obtained malignant and non-malignant tissue from patients with non-small cell lung cancer.
    Lang SM; Stratakis DF; Freudling A; Ebelt K; Oduncu F; Hautmann H; Huber RM
    Eur J Med Res; 2000 Aug; 5(8):341-6. PubMed ID: 10958767
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A fast and convenient new technique to detect the therapeutic target, K-ras mutant, from peripheral blood in non-small cell lung cancer patients.
    Tsao DA; Yang MJ; Chang HJ; Yen LC; Chiu HH; Hsueh EJ; Chen YF; Lin SR
    Lung Cancer; 2010 Apr; 68(1):51-7. PubMed ID: 19589613
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low mutational rate of K-ras codon 12 in singular bronchoscopy specimens in suspected lung cancer.
    Spasova I; Novotna H; Vachtenheim J; Bartosova H; Patek J; Hoserova V; Zatloukal P; Kinkor Z
    Neoplasma; 2005; 52(3):255-9. PubMed ID: 15875089
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel molecular staging protocol for non-small cell lung cancer.
    Miyake M; Adachi M; Huang C; Higashiyama M; Kodama K; Taki T
    Oncogene; 1999 Apr; 18(14):2397-404. PubMed ID: 10327061
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is there a prognostic role of K-ras point mutations in the serum of patients with advanced non-small cell lung cancer?
    Camps C; Sirera R; Bremnes R; Blasco A; Sancho E; Bayo P; Safont MJ; Sánchez JJ; Tarón M; Rosell R
    Lung Cancer; 2005 Dec; 50(3):339-46. PubMed ID: 16139926
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutations of K-ras oncogene and absence of H-ras mutations in squamous cell carcinomas of the lung.
    Vachtenheim J; Horáková I; Novotná H; Opáalka P; Roubková H
    Clin Cancer Res; 1995 Mar; 1(3):359-65. PubMed ID: 9815992
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EGFR, ERBB2, and KRAS mutations in Korean non-small cell lung cancer patients.
    Bae NC; Chae MH; Lee MH; Kim KM; Lee EB; Kim CH; Park TI; Han SB; Jheon S; Jung TH; Park JY
    Cancer Genet Cytogenet; 2007 Mar; 173(2):107-13. PubMed ID: 17321325
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A modified mutagenic PCR-RFLP method for K-ras codon 12 and 13 mutations detection in NSCLC patients.
    Hatzaki A; Razi E; Anagnostopoulou K; Iliadis K; Kodaxis A; Papaioannou D; Labropoulos S; Vasilaki M; Kosmidis P; Saetta A; Mihalatos M; Nasioulas G
    Mol Cell Probes; 2001 Oct; 15(5):243-7. PubMed ID: 11735295
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Distinct epidermal growth factor receptor and KRAS mutation patterns in non-small cell lung cancer patients with different tobacco exposure and clinicopathologic features.
    Tam IY; Chung LP; Suen WS; Wang E; Wong MC; Ho KK; Lam WK; Chiu SW; Girard L; Minna JD; Gazdar AF; Wong MP
    Clin Cancer Res; 2006 Mar; 12(5):1647-53. PubMed ID: 16533793
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic impact of mutated K-ras gene in surgically resected non-small cell lung cancer patients.
    Rosell R; Li S; Skacel Z; Mate JL; Maestre J; Canela M; Tolosa E; Armengol P; Barnadas A; Ariza A
    Oncogene; 1993 Sep; 8(9):2407-12. PubMed ID: 8395679
    [TBL] [Abstract][Full Text] [Related]  

  • 12. K-ras and p16(INK4A)alterations in sputum of NSCLC patients and in heavy asymptomatic chronic smokers.
    Destro A; Bianchi P; Alloisio M; Laghi L; Di Gioia S; Malesci A; Cariboni U; Gribaudi G; Bulfamante G; Marchetti A; Bosari S; Infante M; Ravasi G; Roncalli M
    Lung Cancer; 2004 Apr; 44(1):23-32. PubMed ID: 15013580
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of circulating cancer cells with K-ras oncogene using membrane array.
    Chen YF; Wang JY; Wu CH; Chen FM; Cheng TL; Lin SR
    Cancer Lett; 2005 Nov; 229(1):115-22. PubMed ID: 16157223
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Detection of K-ras oncogene activation in human lung cancer and its possible clinical application].
    Zhang G; Sun Y; Wang M
    Zhonghua Jie He He Hu Xi Za Zhi; 1995 Oct; 18(5):282-4, 317. PubMed ID: 8762479
    [TBL] [Abstract][Full Text] [Related]  

  • 15. K-ras activation in non-small cell lung cancer in the dog.
    Kraegel SA; Gumerlock PH; Dungworth DL; Oreffo VI; Madewell BR
    Cancer Res; 1992 Sep; 52(17):4724-7. PubMed ID: 1324792
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutations of ras genes distinguish a subset of non-small-cell lung cancer cell lines from small-cell lung cancer cell lines.
    Mitsudomi T; Viallet J; Mulshine JL; Linnoila RI; Minna JD; Gazdar AF
    Oncogene; 1991 Aug; 6(8):1353-62. PubMed ID: 1679529
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnostic assay based on hsa-miR-205 expression distinguishes squamous from nonsquamous non-small-cell lung carcinoma.
    Lebanony D; Benjamin H; Gilad S; Ezagouri M; Dov A; Ashkenazi K; Gefen N; Izraeli S; Rechavi G; Pass H; Nonaka D; Li J; Spector Y; Rosenfeld N; Chajut A; Cohen D; Aharonov R; Mansukhani M
    J Clin Oncol; 2009 Apr; 27(12):2030-7. PubMed ID: 19273703
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Detection of K-ras oncogene mutations in human lung cancer by PCR-SSCP-DNA direct sequencing].
    Fang Q; Li X; Li J; Liang S
    Wei Sheng Yan Jiu; 1998 Jan; 27(1):6-8. PubMed ID: 10682630
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of epidermal growth factor receptor overexpression, K-ras point mutation and c-myc amplification in the carcinogenesis of non-small cell lung cancer.
    Sekine I; Takami S; Guang SG; Yokose T; Kodama T; Nishiwaki Y; Kinoshita M; Matsumoto H; Ogura T; Nagai K
    Oncol Rep; 1998; 5(2):351-4. PubMed ID: 9468555
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Widespread molecular alterations present in stage I non-small cell lung carcinoma fail to predict tumor recurrence.
    Baksh FK; Dacic S; Finkelstein SD; Swalsky PA; Raja S; Sasatomi E; Luketich JD; Fernando HC; Yousem SA
    Mod Pathol; 2003 Jan; 16(1):28-34. PubMed ID: 12527710
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.